Kyowa Kirin Co., Ltd. (4151.T) JPX

2,600.50

-31(-1.18%)

Updated at April 03 03:30PM

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Masashi Miyamoto	Chairman & Chief Executive Officer	157M	1959
Abdul Hafeez Mullick	Representative Director, President & COO	0	1967
Hiroki Nakamura	Global Corporate Communications Head	0	N/A
Hiroshi Sonekawa	Managing Executive Officer, Vice President and Head of Sales & Marketing Division	0	N/A
Kazuki Nemoto	Head of Global Legal	0	N/A
Motohiko Kawaguchi	Chief Financial Officer & Managing Executive Officer	0	N/A
Takeyoshi Yamashita	Director, Executive Vice President & Chief Medical Officer	0	1961
Shoko Itagaki	Managing Executive Officer, Chief People Officer & Global Human Resources Head	0	N/A
Naohiko Kubo	Global Finance Head & Accounting Manager	0	N/A
Yasuo Fujii	Chief Strategy Officer, Vice President, Managing Executive Officer & Global BD Head	0	1964

Name

Title

Pay

Year Born

Masashi Miyamoto

Chairman & Chief Executive Officer

157M

1959

Abdul Hafeez Mullick

Representative Director, President & COO

1967

Hiroki Nakamura

Global Corporate Communications Head

N/A

Hiroshi Sonekawa

Managing Executive Officer, Vice President and Head of Sales & Marketing Division

N/A

Kazuki Nemoto

Head of Global Legal

N/A

Motohiko Kawaguchi

Chief Financial Officer & Managing Executive Officer

N/A

Takeyoshi Yamashita

Director, Executive Vice President & Chief Medical Officer

1961

Shoko Itagaki

Managing Executive Officer, Chief People Officer & Global Human Resources Head

N/A

Naohiko Kubo

Global Finance Head & Accounting Manager

N/A

Yasuo Fujii

Chief Strategy Officer, Vice President, Managing Executive Officer & Global BD Head

1964

Description

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.